Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aerie's Netarsudil's Safety Questions May Determine Fate At Advisory Committee

Executive Summary

Proposed treatment for elevated intraocular pressure would be first in new rho-associated protein kinase inhibitor class.

Advertisement

Related Content

Recent And Upcoming FDA Advisory Committee Meetings
Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy
Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing
Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test
User Fee Goal Dates

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS121744

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel